A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 13, 2016

Primary Completion Date

May 30, 2017

Study Completion Date

June 22, 2017

Conditions
Solid Tumor
Interventions
DRUG

Talazoparib

Talazoparib 1 mg orally once daily.

Trial Locations (19)

32806

Orlando Health, Inc., Orlando

33021

Memorial Cancer Institute at Memorial Regional Hospital, Hollywood

Memorial Regional Hospital, Hollywood

33028

Memorial Hospital West, Pembroke Pines

46804

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

46845

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

90095

Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles

TRIO-US Central Administration, Los Angeles

UCLA Hematology/Oncology, Los Angeles

UCLA West Medical Pharmacy. Attn: Steven L. Wong, Pharm.D., Los Angeles

90277

Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates, Redondo Beach

90404

UCLA Hematology/Oncology - Santa Monica, Santa Monica

91105

UCLA Hematology/Oncology - Pasadena, Pasadena

91326

UCLA Hematology/Oncology - Porter Ranch, Porter Ranch

91355

UCLA Hematology/Oncology - Santa Clarita, Valencia

91505

UCLA Hematology/Oncology - Burbank, Burbank

92835

St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton

93309

CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield

90095-7349

UCLA West Medical Pharmacy, Attn: Steven L. Wong, Pharm.D., Los Angeles

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY